This segment focuses on the research, development, and manufacturing of monoclonal antibodies (mAbs) for various therapeutic applications. Sinocelltech utilizes advanced cell line development, protein expression, and purification technologies to produce high-quality mAbs. Research and development activities include target identification, antibody engineering, and preclinical and clinical trials. The company has received marketing approval for ripertamab (SCT-400), a recombinant chimeric anti-CD20 monoclonal antibody, demonstrating its capabilities in this area. This segment addresses unmet medical needs in oncology and immunology, with the potential to expand into other therapeutic areas. Future opportunities include developing next-generation antibody formats and expanding the product pipeline through strategic partnerships and collaborations. Regulatory and clinical aspects are critical, with a focus on obtaining approvals from the NMPA and other regulatory bodies. The company is also considering partnerships with international collaborators to further develop and commercialize its mAb products.

This segment concentrates on the development and industrialization of recombinant proteins and vaccines. Sinocelltech employs advanced technologies in protein expression vectors, cell line development, and serum-free medium development. The company's research and development efforts include process scale-up, protein purification, and formulation. The company has developed vaccine candidates, including SCTV-01C and SCTV-01E, for COVID-19, which have shown positive interim data from phase III trials. This segment addresses the need for innovative vaccines and protein-based therapeutics, with a focus on infectious diseases and other areas. Future opportunities include expanding the vaccine pipeline and developing novel recombinant protein therapeutics. Regulatory compliance and clinical validation are crucial for this segment, with a focus on obtaining approvals from the NMPA and other regulatory agencies. The company is also exploring partnerships with international collaborators to accelerate product development and market access.